MedPath
Found 9 clinical trials|View Analysis
Sort by:

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Phase 2
Recruiting
Conditions
Locally Advanced Chondrosarcoma
Locally Advanced Sinonasal Adenocarcinoma
Metastatic Olfactory Neuroblastoma
Locally Advanced Olfactory Neuroblastoma
Metastatic Sinonasal Undifferentiated Carcinoma
Metastatic Sinonasal Adenocarcinoma
Locally Advanced Large-cell Neuroendocrine Carcinoma
Metastatic Chondrosarcoma
Locally Advanced Sinonasal Undifferentiated Carcinoma
Metastatic Large-cell Neuroendocrine Carcinoma
Interventions
First Posted Date
2023-12-20
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT06176989
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Phase 3
Recruiting
Conditions
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions
First Posted Date
2023-11-13
Last Posted Date
2024-12-11
Lead Sponsor
Servier Bio-Innovation LLC
Target Recruit Count
136
Registration Number
NCT06127407
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇦🇺

Sir Charles Gairdner Hospital, Nedlands, Australia

🇧🇷

Hospital Das Clínicas Da Ufmg, Belo Horizonte, Brazil

and more 35 locations

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Phase 2
Active, not recruiting
Conditions
Central Chondrosarcoma, Grade 2
Central Chondrosarcoma, Grade 3
Dedifferentiated Chondrosarcoma
Metastatic Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma
Metastatic Clear Cell Sarcoma of Soft Tissue
Interventions
Drug: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
First Posted Date
2020-07-07
Last Posted Date
2025-01-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
27
Registration Number
NCT04458922
Locations
🇺🇸

Siteman Cancer Center-South County, Saint Louis, Missouri, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 12 locations

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Phase 2
Active, not recruiting
Conditions
Metastatic Primary Central Chondrosarcoma
Locally Advanced Unresectable Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma
Interventions
Drug: Belinostat
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Decitabine and Cedazuridine
Drug: Guadecitabine
Procedure: Magnetic Resonance Imaging
First Posted Date
2020-04-10
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
32
Registration Number
NCT04340843
Locations
🇺🇸

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

HaysMed, Hays, Kansas, United States

and more 36 locations

Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma

Not Applicable
Withdrawn
Conditions
Metastatic Chondrosarcoma
Interventions
Radiation: Lattice stereotactic body radiation therapy
First Posted Date
2019-09-23
Last Posted Date
2020-09-16
Lead Sponsor
Washington University School of Medicine
Registration Number
NCT04098887

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Phase 1
Terminated
Conditions
Metastatic Leiomyosarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma
Refractory Undifferentiated Pleomorphic Sarcoma
Advanced Synovial Sarcoma
Advanced Undifferentiated Pleomorphic Sarcoma
Advanced Leiomyosarcoma
Metastatic Synovial Sarcoma
Refractory Leiomyosarcoma
Refractory Round Cell Liposarcoma
Refractory Soft Tissue Sarcoma
Interventions
Drug: Itacitinib
Other: Laboratory Biomarker Analysis
First Posted Date
2018-09-13
Last Posted Date
2024-05-08
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
27
Registration Number
NCT03670069
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Phase 2
Completed
Conditions
Chondrosarcoma
Metastatic Chondrosarcoma
Interventions
First Posted Date
2011-04-07
Last Posted Date
2023-03-10
Lead Sponsor
George Clinical Pty Ltd
Target Recruit Count
47
Registration Number
NCT01330966
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Edward Cancer Center, Naperville, Illinois, United States

and more 4 locations

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Phase 2
Active, not recruiting
Conditions
Clear Cell Chondrosarcoma
Dedifferentiated Chondrosarcoma
Mesenchymal Chondrosarcoma
Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma
Locally Advanced Chondrosarcoma
Metastatic Chondrosarcoma
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacogenomic Study
Drug: Vismodegib
First Posted Date
2010-12-29
Last Posted Date
2024-07-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
45
Registration Number
NCT01267955
Locations
🇫🇷

Centre Oscar Lambert, Lille, France

🇫🇷

Centre Leon Berard, Lyon, France

🇫🇷

Hopital De La Timone, Marseille, France

and more 3 locations

S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma

Phase 2
Completed
Conditions
Sarcoma
Interventions
First Posted Date
2005-04-06
Last Posted Date
2012-01-18
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
75
Registration Number
NCT00107419
Locations
🇺🇸

Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States

🇺🇸

CCOP - Carle Cancer Center, Urbana, Illinois, United States

🇺🇸

Rush-Copley Cancer Care Center, Aurora, Illinois, United States

and more 54 locations
© Copyright 2025. All Rights Reserved by MedPath